Correlation Between Inhibrx and Achilles Therapeutics

Can any of the company-specific risk be diversified away by investing in both Inhibrx and Achilles Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibrx and Achilles Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Inhibrx and Achilles Therapeutics PLC, you can compare the effects of market volatilities on Inhibrx and Achilles Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibrx with a short position of Achilles Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibrx and Achilles Therapeutics.

Diversification Opportunities for Inhibrx and Achilles Therapeutics

0.45

Correlation Coefficient

Inhibrx  Achilles Therapeutics

Very weak diversification

The 3 months correlation between Inhibrx and Achilles is 0.45. Overlapping area represents the amount of risk that can be diversified away by holding Inhibrx and Achilles Therapeutics PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Achilles Therapeutics PLC and Inhibrx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibrx are associated (or correlated) with Achilles Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Achilles Therapeutics PLC has no effect on the direction of Inhibrx i.e., Inhibrx and Achilles Therapeutics go up and down completely randomly.

Pair Corralation between Inhibrx and Achilles Therapeutics

Given the investment horizon of 90 days Inhibrx is expected to under-perform the Achilles Therapeutics. In addition to that, Inhibrx is 1.11 times more volatile than Achilles Therapeutics PLC. It trades about -0.01 of its total potential returns per unit of risk. Achilles Therapeutics PLC is currently generating about 0.15 per unit of volatility. If you would invest  118.00  in Achilles Therapeutics PLC on December 29, 2024 and sell it today you would earn a total of  30.00  from holding Achilles Therapeutics PLC or generate 25.42% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	91.8%
Values	Daily Returns

Inhibrx  vs.  Achilles Therapeutics PLC

Inhibrx

Risk-Adjusted Performance

Very Weak

Over the last 90 days Inhibrx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental drivers, Inhibrx is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Achilles Therapeutics PLC

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Achilles Therapeutics PLC are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite quite weak technical indicators, Achilles Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Inhibrx and Achilles Therapeutics

The main advantage of trading using opposite Inhibrx and Achilles Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibrx position performs unexpectedly, Achilles Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Achilles Therapeutics will offset losses from the drop in Achilles Therapeutics' long position.

The idea behind Inhibrx and Achilles Therapeutics PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.